Panacea Biotec Peer Comparison

NSE: PANACEABIO | BSE: 531349

₹360.65

₹4.70 (1.32%)

As on 09-Nov-2026IST

Market cap

₹2,215 Cr

Revenue (TTM)

₹673 Cr

P/E Ratio

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	2,215	18,276	19,011	17,931	17,516
Revenue (₹ Cr)	673	1,842	2,287	2,654	3,330
Net Profit (₹ Cr)	-8.92	308.62	678.07	859.38	720.77
Net Margin (%)	-1.30	16.63	28.10	30.42	21.60
RoE (%)	-1.37	11.81	19.73	18.58	18.93
Price to Earnings	--	54.98	28.57	20.86	24.76
Price-To-Book	2.65	6.63	5.18	4.09	4.23

Income Statement (₹ Cr)

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	672.64	1,841.62	2,287.33	2,654.29	3,329.63
Total Income	688.11	1,855.87	2,413.29	2,825.39	3,337.47
Total Expenditure	670.45	1,328.95	1,490.75	1,681.39	2,168.88
EBITDA	2.19	512.67	796.58	972.90	1,160.75
Depreciation	32.57	130.47	78.10	57.71	285.40
EBIT	-30.38	382.20	718.48	915.19	875.35
Interest	6.37	49.12	0.88	8.91	187.51
Other Income	15.47	14.25	125.96	171.10	7.84
Exceptional Items	10.92	11.73	0.00	82.90	-53.14
Profit before Tax	-10.36	359.06	843.56	1,160.28	642.54
Provision for Tax	-1.44	50.44	165.49	300.90	-78.23
Profit after Tax	-8.92	308.62	678.07	859.38	720.77

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	834.84	2,757.68	3,586.42	4,385.41	4,144.34
Minority Interest	1.80	0.00	-12.71	0.00	-10.85
Non-Current Liabilities	84.61	363.37	28.74	222.21	758.48
Current Liabilities	348.68	1,016.50	385.94	685.36	2,681.14
Total Liabilities	1,262.18	3,705.61	4,037.51	4,921.88	7,246.72

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	719.70	2,763.86	1,291.22	905.21	5,578.78
Current Assets	513.04	1,277.15	2,585.66	4,024.56	1,800.86
Total Assets	1,262.18	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	23.66	657.97	0.57	2.50	2,309.68
Net Current Assets	164.36	260.65	2,199.72	3,339.20	-880.28
Contingent Liabilities	416.47	160.01	17.53	370.49	51.57

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	16.69	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-40.50	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-1.06	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-24.86	29.88	-105.52	-392.41	-145.00

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	-0.15	11.43	24.97	23.39	14.47
ROE (%)	-1.37	11.81	19.73	18.58	18.93
ROA (%)	-0.70	8.09	18.69	17.36	9.78
EBIT Margin (%)	-4.52	20.75	31.41	34.48	26.29
Net Margin (%)	-1.30	16.63	28.10	30.42	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	10.26	37.26	15.01	11.75	11.06
EBIT Growth (%)	36.14	56.89	18.45	21.45	13.71
Net Profit Growth (%)	-180.22	127.86	19.61	2.39	60.98
EPS Growth (%)	99.13	5.65	17.73	13.17	80.38
Book Value Growth (%)	0.01	9.67	26.75	-0.34	36.71

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	-193.96	57.89	28.57	22.47	22.92
Price / Book Value	2.65	6.63	5.18	4.09	4.23
Dividend Yield (%)	0.00	0.06	0.32	1.91	0.00
EV/EBITDA	988.03	36.84	22.60	15.24	17.02
Market Cap (₹ Cr)	1,813.89	6,819.66	11,439.22	21,592.90	17,980.08

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.03	0.08	0.00	0.00	0.10
Short term debt to equity ratio	--	0.16	0.00	0.00	0.12
Current Ratio	1.47	1.26	6.70	5.87	0.67
Quick Ratio	0.92	0.82	5.59	5.23	0.49
Interest Coverage	-0.63	8.31	959.59	131.22	4.43

	Panacea Biotec	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	10.93	29.09	36.10	9.10	18.98
Asset Turnover	0.53	0.48	0.63	0.54	0.45
Receivable days	40.93	113.81	121.68	26.06	63.88
Inventory Days	113.89	84.76	63.83	65.95	43.27
Payable days	270.26	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-115.43	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.